scholarly article | Q13442814 |
P50 | author | Carl H. June | Q19277113 |
Alfred L Garfall | Q80726281 | ||
Edward A. Stadtmauer | Q85544110 | ||
Megan M. Davis | Q85544115 | ||
Irina Kulikovskaya | Q85544118 | ||
Anne Lamontagne | Q85544147 | ||
Donald L. Siegel | Q85544150 | ||
Bruce L. Levine | Q85544154 | ||
Regina M. Young | Q85544157 | ||
Michael C Milone | Q88137713 | ||
Emily C Ayers | Q89776169 | ||
Jan Melenhorst | Q90374440 | ||
Martin Carroll | Q92827331 | ||
Brendan M Weiss | Q95945848 | ||
Kavita Dhodapkar | Q98394175 | ||
Naseem D S Kerr | Q117283215 | ||
Karen Dengel | Q117283217 | ||
Maria Krevvata | Q117283232 | ||
Selene Nunez-Cruz | Q117283233 | ||
Marcela V. Maus | Q38321614 | ||
William Matsui | Q38326712 | ||
Dan T Vogl | Q42576934 | ||
Simon F Lacey | Q56978267 | ||
Adam D Cohen | Q63987185 | ||
P2093 | author name string | Qiuju Wang | |
Rituparna Das | |||
Patricia A Mangan | |||
Wei-Ting Hwang | |||
Madhav V Dhodapkar | |||
P2860 | cites work | Core transcriptional regulatory circuitry in human embryonic stem cells | Q24322016 |
Characterization of clonogenic multiple myeloma cells | Q24610291 | ||
Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance | Q24644883 | ||
Chimeric antigen receptor T cells for sustained remissions in leukemia | Q29617588 | ||
Salvage second hematopoietic cell transplantation in myeloma | Q30416452 | ||
Identification of translocation products but not K-RAS mutations in memory B cells from patients with multiple myeloma | Q33590627 | ||
Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of Costimulated autologous T cells. | Q33687086 | ||
Differentiation stage of myeloma plasma cells: biological and clinical significance. | Q33712516 | ||
NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. | Q34485950 | ||
International uniform response criteria for multiple myeloma. | Q34549410 | ||
Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma. | Q34557946 | ||
Transfer of influenza vaccine-primed costimulated autologous T cells after stem cell transplantation for multiple myeloma leads to reconstitution of influenza immunity: results of a randomized clinical trial. | Q34568939 | ||
Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma | Q35652021 | ||
Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma | Q36206430 | ||
Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy | Q36229280 | ||
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma | Q36284584 | ||
Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy | Q36322760 | ||
The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell | Q36362222 | ||
Stemness of B-cell progenitors in multiple myeloma bone marrow | Q36405908 | ||
Metastatic Latency and Immune Evasion through Autocrine Inhibition of WNT. | Q36731080 | ||
A monoclonal gammopathy precedes multiple myeloma in most patients | Q37209020 | ||
The multiple roles for Sox2 in stem cell maintenance and tumorigenesis | Q37411246 | ||
Frequency and kinetics of polyclonal and clonal B cells in the peripheral blood of patients being treated for multiple myeloma | Q73281262 | ||
Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice | Q73386754 | ||
Levels of circulating CD19+ cells in patients with multiple myeloma | Q74160384 | ||
Leukemic B cells clonally identical to myeloma plasma cells are myelomagenic in NOD/SCID mice | Q77738087 | ||
Clonotypic myeloma cells able to xenograft myeloma to nonobese diabetic severe combined immunodeficient mice copurify with CD34 (+) hematopoietic progenitors | Q78358421 | ||
Extramedullary vs medullary relapse after autologous or allogeneic hematopoietic stem cell transplantation (HSCT) in multiple myeloma (MM) and its correlation to clinical outcome | Q80937605 | ||
Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients | Q82242208 | ||
CD138-negative clonogenic cells are plasma cells but not B cells in some multiple myeloma patients | Q83696156 | ||
Growth differentiating factor 15 enhances the tumor-initiating and self-renewal potential of multiple myeloma cells. | Q37535244 | ||
Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. | Q37599478 | ||
Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases | Q37626783 | ||
Myeloma stem cell concepts, heterogeneity and plasticity of multiple myeloma. | Q38151195 | ||
Multiple Myeloma Includes Phenotypically Defined Subsets of Clonotypic CD20+ B Cells that Persist During Treatment with Rituximab | Q38260684 | ||
Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group | Q39214847 | ||
Patients with multiple myeloma develop SOX2-specific autoantibodies after allogeneic stem cell transplantation | Q39424061 | ||
T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma | Q40096913 | ||
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia | Q41429394 | ||
In multiple myeloma, clonotypic B lymphocytes are detectable among CD19+ peripheral blood cells expressing CD38, CD56, and monotypic Ig light chain | Q42674911 | ||
Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma | Q42762683 | ||
Extramedullary relapses after allogeneic non-myeloablative stem cell transplantation in multiple myeloma patients do not negatively affect treatment outcome. | Q43880095 | ||
Molecular remission of CML after autotransplantation followed by adoptive transfer of costimulated autologous T cells | Q44632359 | ||
Targeting CD138-/CD20+ Clonogenic Myeloma Precursor Cells Decreases These Cells and Induces Transferable Antimyeloma Immunity. | Q45026469 | ||
Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma. | Q46027082 | ||
Gastrointestinal graft-versus-host disease in recipients of autologous hematopoietic stem cells: incidence, risk factors, and outcome | Q46916861 | ||
Cancer stem cells revisited | Q49557760 | ||
Two States of Myeloma Stem Cells | Q50077900 | ||
SOX2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinoma | Q50454918 | ||
Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. | Q51987984 | ||
Isolated Extramedullary Relapse of Acute Leukemia after Allogeneic Stem Cell Transplantation: Different Kinetics and Better Prognosis than Systemic Relapse. | Q52777420 | ||
Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage. | Q52868194 | ||
CD19-CD45 low/- CD38 high/CD138+ plasma cells enrich for human tumorigenic myeloma cells. | Q53370464 | ||
A high frequency of circulating B cells share clonotypic Ig heavy-chain VDJ rearrangements with autologous bone marrow plasma cells in multiple myeloma, as measured by single-cell and in situ reverse transcriptase-polymerase chain reaction. | Q54122476 | ||
Circulating monoclonal B cells expressing P glycoprotein may be a reservoir of multidrug-resistant disease in multiple myeloma. | Q54216497 | ||
Multiple Myeloma: Diagnosis and Treatment. | Q55119496 | ||
In multiple myeloma, circulating hyperdiploid B cells have clonotypic immunoglobulin heavy chain rearrangements and may mediate spread of disease | Q56991213 | ||
Donor T-cell responses and disease progression patterns of multiple myeloma | Q57560891 | ||
Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile | Q60203403 | ||
Circulating monotypic B-cells in multiple myeloma: association with lambda paraproteins | Q69218609 | ||
Circulating clonal lymphocytes in myeloma constitute a minor subpopulation of B cells | Q71087704 | ||
The blood B-cells and bone marrow plasma cells in patients with multiple myeloma share identical IgH rearrangements | Q71682102 | ||
The proliferative potential of myeloma plasma cells manifest in the SCID-hu host | Q73160451 | ||
P433 | issue | 8 | |
P577 | publication date | 2018-04-19 | |
P1433 | published in | JCI insight | Q27727187 |
P1476 | title | Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma | |
P478 | volume | 3 |